

รายการอ้างอิง

- [1] Gupta, N., Limbago, B.M., Patel, J.B., Kallen, A.J. Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention. Clinical Infectious Diseases 53 (2011): 60-67.
- [2] Yigit, H., Queenan, A.M., Anderson, G.J., Domenech-Sanchez, A., Biddle, J.W., Steward, C.D., et al. Novel Carbapenem-Hydrolyzing β -Lactamase, KPC-1, from a Carbapenem-Resistant Strain of *Klebsiella pneumoniae*. Antimicrobial Agents and Chemotherapy 45 (2001): 1151-1161.
- [3] Kanj, S.S., Kanafani, Z.A. Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant *Pseudomonas aeruginosa*. Mayo Clinic Proceedings 86 (2011): 250-259.
- [4] Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycycline antimicrobial agent. Diagnostic Microbiology and Infectious Disease 52 (2005): 165-171.
- [5] Sader, H.S., Farrell, D.J., Jones, R.N. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and *Acinetobacter* spp. isolated in US medical centers (2005–2009). Diagnostic Microbiology and Infectious Disease 69 (2011): 223-227.
- [6] Castanheira, M., Sader, H.S., Deshpande, L.M., Fritsche, T.R., Jones, R.N. Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo- β -Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy 52 (2007): 570-573.
- [7] Poulakou, G., Kontopidou, F.V., Paramythiotou, E., Kompoti, M., Katsiari, M., Mainas, E., et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. Journal of Infection 58 (2009): 273-284.
- [8] Ku, K., Pogue, J.M., Moshos, J., Bheemreddy, S., Wang, Y., Bhargava, A., et al. Retrospective evaluation of colistin versus tigecycline for the treatment of *Acinetobacter baumannii* and/or carbapenem-resistant Enterobacteriaceae infections. American Journal of Infection Control (2012).
- [9] Tygacil® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.;2011.
- [10] Treyprasert, W., Schmidt, S., Rand, K.H., Suvanakoot, U., Derendorf, H. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin



1786532146

- against four different bacterial strains. International Journal of Antimicrobial Agents 29 (2007): 263-270.
- [11] Tasso, L., de Andrade, C., Dalla Costa, T. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against *Streptococcus pneumoniae*. International Journal of Antimicrobial Agents 38 (2011): 307-313.
- [12] Wiskirchen, D.E., Koomanachai, P., Nicasio, A.M., Nicolau, D.P., Kuti, J.L. In Vitro Pharmacodynamics of Simulated Pulmonary Exposures of Tigecycline Alone and in Combination against *Klebsiella pneumoniae* Isolates Producing a KPC Carbapenemase. Antimicrobial Agents and Chemotherapy 55 (2011): 1420-1427.
- [13] CLSI(2012) Performance standards for antimicrobial susceptibility testing:M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute.
- [14] United States Food and Drug Administration (FDA), TYGACIL® (TIGECYCLINE) FOR INJECTION.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s016lbl.pdf (accessed 10 Dec 2012).
- [15] European Society of Clinical Microbiology Infectious Diseases. 2011. Clinical breakpoints. In European Committee on Antimicrobial Susceptibility Testing (ed). <http://www.eucast.org/>.
- [16] Mueller, M., de la Pena, A., Derendorf, H. Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC. Antimicrobial Agents and Chemotherapy 48 (2004): 369-377.
- [17] Edgar L Schuck, H.D. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Review of Anti-infective Therapy 3 (2005): 361–373.
- [18] Stephan Schmidt , E.S., Vipul Kumar , Olaf Burkhardt, Hartmut Derendorf. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves. Expert Opinion on Drug Discovery 2 (2007): 849-860.
- [19] Arno Nolting, T.D.C., Kenneth H. Rand, Hartmut Derendorf. Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in vitro. Pharmaceutical Research 13 (1996): 91-96.
- [20] Liu, Q., Rand, K., Derendorf, H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin–tazobactam combinations. International Journal of Antimicrobial Agents 23 (2004): 494-497.



- [21] Peña, A.d.l., Gräbe, A., Rand, K.H., Rehak, E., Gross, J., Thyroff-Friesinger, U., et al. PK-PD modelling of the effect of cefaclor on four different bacterial strains. International Journal of Antimicrobial Agents 23 (2004): 218-225.
- [22] Liu, P., Rand, K.H., Obermann, B., Derendorf, H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. International Journal of Antimicrobial Agents 25 (2005): 120-129.
- [23] Tam, V.H. Modelling time-kill studies to discern the pharmacodynamics of meropenem. Journal of Antimicrobial Chemotherapy 55 (2005): 699-706.
- [24] Johan W. Mouton, A.A.V. Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics The Minimum Inhibitory Concentration versus Stationary Concentration. Clin Pharmacokinet 44 (2005): 201-210.
- [25] Schuck, E.L., Dalhoff, A., Stass, H., Derendorf, H. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*. Infection 33 (2005): 22-28.
- [26] Pournaras, S., Vrioni, G., Neou, E., Dendrinos, J., Dimitroulia, E., Poulou, A., et al. Activity of tigecycline alone and in combination with colistin and meropenem against *Klebsiella pneumoniae* carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. International Journal of Antimicrobial Agents 37 (2011): 244-247.



1786632146

ภาคผนวก



ภาคผนวก ก
แบบบันทึกข้อมูลทั่วไปของเชื้อแบคทีเรีย
วันที่ ชื่อเชื้อ

หมายเลขเชื้อ (isolate No.)	แหล่งที่คัดแยก	Zone of inhibition (mm)	Susceptible (S/I/R)

หมายเลขเชื้อ (isolate No.)	แหล่งที่คัดแยก	ค่าความเข้มข้นต่ำสุดที่สามารถยับยั้งเชื้อ (minimum inhibitory concentration: MIC)	
		ชุดที่ 1	ชุดที่ 2



1788632146

ต้นฉบับ หน้าขาดหาย

ประวัติผู้เขียนวิทยานิพนธ์

นางสาวมัณฑนา ทะลี เกิดเมื่อวันที่ 2 มกราคม พ.ศ. 2528 สำเร็จการศึกษาปริญญาตรี
เภสัชศาสตรบัณฑิต คณะเภสัชศาสตร์ มหาวิทยาลัยศิลปากร เมื่อปีการศึกษา 2549 และเข้าศึกษาต่อ
ในหลักสูตรเภสัชศาสตรมหาบัณฑิต สาขาเภสัชกรรมคลินิก คณะเภสัชศาสตร์ จุฬาลงกรณ์
มหาวิทยาลัย ปีการศึกษา 2554 ปัจจุบันปฏิบัติงานในตำแหน่งเภสัชกร กลุ่มงานเภสัชกรรมชุมชน
โรงพยาบาลสมเด็จพระยุพราชสายบุรี อำเภอสายบุรี จังหวัดปัตตานี

